Patient Engagement Drives Clinical and Commercial Success

Author(s): Amy Bucher

The past half-decade has ushered in a period of high-velocity innovation in life sciences. At the start of 2020, few outside of specialised circles had heard of mRNA vaccines, GLP-1 receptor agonists, or CRISPR-based therapies. These therapeutic categories have not only been making headlines in 2026; they are fundamentally reshaping both clinical practice and commercial strategy across the industry.

Yet, even the most groundbreaking therapies remain subject to the realities of human behaviour. Realising the full promise of these innovations, whether measured in improved health outcomes or commercial success, depends on people: volunteers who enrol in clinical trials, participants who adhere to study protocols, providers who prescribe new treatments, and patients who follow through with their therapies. As the cost and novelty of new therapies rise, so too do the barriers to participation and adherence at every stage. Patient engagement, therefore, is more critical than ever and requires the same level of innovation as the therapies themselves.